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DR. TYLER: Chronic pulmonary emphysema is one of the two pathological en-
tities commonly seen in lungs from horses with the clinical sign of "heaves." The
other pathologic entity commonly seen in lungs from horses with this clinical sign is
bronchitis and bronchiolitis. Occasionally both pathologic conditions are seen.
It is difficult to clinically differentiate the cause of "heaves." Generally, horses
which show marked clinical improvement if the environment of diet is radically
changed, or which respond to the usual antibiotic and antihistamine treatment, will
have bronchiolitis. Those which do not respond usually have chronic pulmonary em-
physema. Respiratory flow rates, flow patterns, and pulmonary resistance measure-
ments in the standing horse before and after administration of bronchial dilaters are
also useful in differentiating emphysema from bronchial disease. Upon completion of
clinical examination, the horse may be necr6psied and the lungs examined and fixed
by continuous infusion via the trachea at 30 cm. of water pressure using a modifica-
tion of the method described by Heard.
Initial physiological studies concerned blood pH, 02, and C02 tensions in exercised
control and "heavy" horses. Horses with clinical signs have blood oxygen tensions
significantly lower than those of control horses, the difference being exaggerated by
exercise. The blood pKa of these horses was significantly lower than that of the con-
trol horses following exercise, but no difference could be demonstrated between the
blood CO2 tensions of the two groups. The diseased horses develop severe dyspnea
with moderate exercise, whereas control horses show few signs of fatigue.
Differences in respiratory flow rates, volumes, and associated intrathoracic pressure
changes were abnormal in diseased horses. Inspiratory flow rates were found to be
higher, tidal volumes lower, and intrathoracic pressure changes greater in diseased
horses than in control horses. Of special importance is the greater expiratory re-
sistance associated with pronounced clinical symptoms.
Horses with clinical signs of "heaves" were demonstrated to have significantly
greater than normal heart rates, total peripheral vascular resistance, pulmonary
vascular resistance, and mean pulmonary artery blood pressure. They also suffered a
highly significant decrease in central blood volume, stroke volume, stroke index, and
left ventricular work; cardiac output was significantly lower. There were no signifi-
cant differences in arterial or right ventricular blood pressures.
At the present time we are studying the pulmonary diffusion capacity for carbon
monoxide in paired horses. Our preliminary conclusion is that the amount of venti-
lated surface available for gas diffusion is less than normal in the horses with "heaves."
DR. CARRINGTON: In a limited series of horses that I have autopsied with Dr.
John House, we found one example of pulmonary emphysema in a clinically normal
animal. I wonder if Dr. Tyler has had that experience, too.
As I understand it, Dr. Tyler feels he can differentiate the chronic bronchiolitis
from emphysema clinically or by diet or use of steroids. Are you ready to give up the
terms, chronic respiratory disease or heaves, and use this more specific one now as we
are trying to do in human medicine?
DR. TYLER: Yes. The answer to the first question is very definitely yes. Don't
you see at necropsy the pathologic entity emphysema without a history of shortness
of breath?
People may die of emphysema, whereas horses are killed when they are no longer
economically usable. We have never had a horse die of emphysema; the disease is
never permitted to progress that far.
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In answer to your second question, we are trying to do that. We use the term
"heaves" in the broad sense of a clinical sign. After manipulation we sometimes feel
that we can say which disease the horse may have.
DR. KILBURN: I would like to throw out the notion that emphysema is not very
often fatal in humans. Patients die of all kinds of complications of airway obstruction
or of cardiovascular failure. But we have now looked at about 400 episodes of acute
respiratory failure in our hospitals and almost 100 deaths. A very small proportion of
cases of acute respiratory failure do not reveal various complications, e.g., acute
airway obstruction, myocardial infarction, gram-negative pneumonia and oxygen
toxicity. I rarely see a death from uncomplicated emphysema.
DR. FARR: Drs. Roy Patterson, Charles Reed, and Paul Van Arsdel made ref-
erence to the fifth class of immunoglobulin, gamma E, as if it were perhaps the only
reaginic antibody capable of mediating the allergic states such as asthma and rhinitis.
This is based on the beautiful work of Ishizaki. I would like to interject the thought
that there may well be more than one class of immunoglobulin with reaginic activity.
Drs. Robert Reid and Percy Minden in our laboratory have performed three types of
experiments which suggest heterogeneity among reaginic antibodies. First, in eluates
from DEAE columns, there is reaginic activity in fractions which contain only de-
tectable gamma G, fractions which contain gamma G, gamma A, and gamma D and
fractions that contain gamma G, some gamma A, and occasionally gamma M. This
implies an electrical charge difference between populations of antibody with reaginic
capacity. Secondly, some of these fractions with reaginic activity are resistant to
treatment with 0.1 molar 2-mercaptoethanol where others are not resistant to such
treatment. This implies a structural difference involving sulfhydryl groups between
populations of antibody with reaginic capacity.
The third piece of evidence is that DEAE peak 1 from normal serum, which con-
contains only detectable gamma G, has a capacity to cuupy the receptor sites in normal
skin to block the passive transfer of DEAE peak 1 reaginic activity derived from
"allergic serum." Conversely, the same normal DEAE peak 1 cannot block the reaginic
activity in peak 3 from reaginic serum. This implies that the Fc fragment of normal
gamma G can compete with the Fc portion of reaginic antibody derived from peak 1,
but it can't compete with the Fc portion of reaginic antibody derived from peak 3.
This denotes structural differences in Fc fragment of reagin in peaks 1 and 3. Taken
as a whole, these data suggest reaginic activity is associated with more than one class
of immunoglobulin or that gamma E is the most heterogenous class of immunoglobulin
so far described.
DR. ROY PATTERSON: I agree that all reaginic activity is not in IgE. I think
it has been conclusively demonstrated that reaginic activity can occur in immunoglob-
ulin G fractions as Dr. Farr states. The results of our studies on spontaneous recur-
ring reaginic antibodies in human, monkey, and dog sera, however, consistently show
localization in immunoglobulin E fractions.
DR. REED: I would like to clarify my remarks on this point Dr. Farr is quite
right, as there is a considerable body of evidence which indicates more than one im-
munoglobulin class to carry this kind of activity. For example, in a study by Stech-
schulte, Auste, and Block of reaginic-like antibody in the rat, one fraction of serum
was found to liberate histamine from mast cells. Another immunoglobulin liberated
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slow-reacting substance from peritoneal exudate cells. Thus, there is evidence for
more than one type of reaginic antibody.
DR. SZENTIVANYI: Since the pertussis-sensitized mouse as a laboratory model
for the investigation of bronchial asthma has been introduced in our laboratory, I
feel that it is my duty to inform you of some recent findings which I think will further
support the ideas presented by Dr. Reed.
We have now shown the following:
(1) It is the endotoxin component of the pertussis cell, and not the so-called "hista-
mine sensitizing factor" (HSF), which is responsible for an increase in the histidine
decarboxylase activity in the pertussis-sensitized mouse. Thus, this increased enzymatic
activity cannot account for the histamine-sensitizing capacity of the pertussis cell.
(2) HSF is capable of blocking in titro the inhibitory activity of epinephrine toward
the incorporation of radioactive glucose into glycogen (a beta adrenergic function) in
the isolated diaphragm preparation.
(3) Extensive structure-activity relationship studies showed that the histamine-
sensitizing activity of the beta adrenergic blocking agents is specific, i.e, it is due to
their ability to inhibit the beta pharmacological actions of the adrenergic neurotrans-
mitters or those of their exogenous counterparts.
(4) Similar to whole pertussis cell, HSF also can produce lymphoid hyperplasia.
Thus, the component of the pertussis cell exhibiting beta adrenergic blocking proper-
ties may not only be responsible for the pharmacological hypersensitivity, but might
also account for the immunological adjuvant activity of pertussis. The latter is be-
lieved to be accomplished through the elimination of the normal beta adrenergic in-
hibition of glucose uptake in the immunocompetent cell. This could conceivably result
in an increased intracellular availability of glucose derivatives in enhancing the mitotic
activity of the immunocompetent cell (rate of entry of glucose is believed to be the
rate-limiting step in controlling mitotic rate in certain cells). Increased mitosis of
the immunocompetent cell would then explain the mechanism of the immunological
adjuvant activity.
It seems to me the central question of Dr. Reed's presentation should be rephrased.
If we were to do that' then most of those differences he has found between bronchial
asthma as a disease entity and the activity pattern of the pertussis-sensitized mouse
could be practically reduced to zero. Specifically, could the Bordetella pertussis-sensi-
tized mouse be used as a model for the investigation of the nature of the "constitutional
abnormality" in bronchial asthma? By "constitutional abnormality" I am referring to
the nature of that factor which determines in any randomly selected population that
only a certain segment of the total population will become asthmatic or will respond
differently from the majority, despite the nearly identical conditions of antigenic ex-
posure presumed to be present for the entire population.
DR. ABINANTI: I would like to get the discussion back to more broadly based
immunologic phenomena. Outstanding studies have been made by the group at the
Scripps Institute on the damaging effects of antigen-antibody complexes on the base-
ment membrane of the kidney. Since a somewhat similar basement membrane exists
in the lung, would it not be profitable to investigate the possibility of such changes in
the basement membrane of the lung?
DR. VAN ARSDEL: First of all, the model that I spoke of would be designed to
assess the significance of antigen-antibody precipitates in the pulmonary vascular
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system. In association with this, we ought to look for basement membrane thickening;
if it does develop, then look for antigen or antibody.
From some of the more classic experiments in rabbit anaphylaxis involving pri-
marily the pulmonary vasculature, there is no evidence of a direct effect of antigen
or antibody on the basement membrane. In experimental glomerulonephritis the con-
ditions are entirely different. The effect of antigen-antibody depends on antigen being
in excess, so that actually it is the soluble complexes which produce kidney damage
associated with basement membrane lesions. Incidentally, in no instance that I know
of in pigeon fanciers' disease, or in the analogous disorders, has there been any evi-
dence of renal involment.
DR. PHILIP PATERSON: One important question is the relationship any im-
mune response to pigeon material has to the disease in question. It is conceivable that
antibody, if directly implicated, might be made locally in the lung. What is seen in
the serum could be "spillover." A meaningful correlation, thus, might be found with
amount of antibody in lung biopsy material. Nor should we overlook the possibility
of a cell-mediated response to pigeon antigens. Have you looked into the matter of
lymphocyte transformation of these patients using pigeon serum or pigeon extract as
antigens?
DR. VAN ARSDEL: In answer to your first question, one reason why efforts to
sensitize animals would be important is to see if serum antibody does indeed produce
lung damage in the presence of antigen. The next step would be the development of an
appropriate actively-sensitized animal. It is very difficult to obtain lung biopsies from
human subjects under the proper conditions for preparation of the sections for fluo-
rescent localization studies. In fact, our only successful one was obtained four years
ago. You are quite right to emphasize that we are not certain at all that the circulating
antibody is responsible. However, it does mediate tissue damage in skin.
Regarding cell-associated or tuberculin type of sensitivity, the only bit of evidence
we have is that the skin reaction follows the course of an Arthus phenomenon and is
practically completely gone at the time the tuberculin-type reaction would be at its
maximum.
DR. REED: A biopsy of one of the patients was studied by fluorescent antibody
technique. Unfortunately, our reagents were not satisfactory, but we did look at a
section of the lung under the electron microscope. Most impressive was that many of
the cells were loaded with endoplasmic reticulum and had the appearance of making
lots of antibody locally. Also the serum of these patients looked like the serum of
rabbits which have been immunized with the aid of an adjuvant. I am not aware of
any other disease of man which has produced such a striking antibody response. We
have wondered if the reason is that they are not also immunized with the adjuvant in
the fecal extracts and the other gram-negative sources of endotoxin.
We also strongly suspect there may be a cellular hypersensitivity. Dr. Van Arsdel's
slides showed one of his patients to have little precipitating antibody. This was the
patient on whom we did the lung biopsy. She was the sickest in the group and had
the least amount of precipitating antibody. Her beta 1-C globulin was not low, as one
would expect in an acute Arthus type of hypersensitivity, but was actually high. Thus,
we have several reasons for suspecting that this may be a mixture of hypersensitivities,
both Arthus and tuberculin types.
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DR. CARRINGTON: I would like to respond briefly to Dr. Abinanti's request for
speculation on the basement membranes. There are two basement membranes, perhaps
not identical, that might be of concern. One is the so-called basement membrane thicken-
ing of the bronchi in asthma, studied with variable results in the human material. The
basement membrane of the epithelium of the alveoli has been considered possibly to
represent an important site of injury in the lesions I have described. In part this
speculation relates to the fact that some 20 or 25 per cent of such patients also have
a collagen disease. Thus, a similarity to the renal lesions which you were mentioning
has been suggested.
There is one system that Dr. Klaus Bensch and others have studied in which the
alveoli are damaged with carbon dioxide. Although the epithelium becomes necrotic
and disintegrates into hyaline membranes, there is no damage to the basement mem-
brane itself. In this system, there is complete recovery. I suspect the same is true of
the mercury lesion, although it has not yet been appropriately studied. I also suspect
that the basement membrane is damaged from exposure to cadmium and ozone.
Whether basement membrane damage represents only a quantitative difference in
severity of damage, or is a critical lesion in determining organization versus resolution
is not yet known. Since Dr. Spiro, an electron microscopist from Dr. Thomas Cottrell's
laboratory is with us, we will be able to learn something about the ultra structure of
the experimental lesion.
To go back to the other discussion, I would like to ask both Dr. Patterson and Dr.
Reed whether multiple exposures in their system ever lead to irreversible change, in
terms of either pulmonary function or morphology.
DR. ROY PATTERSON: In regard to our systems, no. Although we have not
reached the point where we have a system of exposing any of these animal systems
chronically, this could be done. It would, of course, require considerable caution be-
cause of the problem of environmental exposure of laboratory personnel to these
antigens which easily sensitize the atopic individual. Also Ascaris sensitizes apparently
non-atopic individuals rather easily. One of our dogs has been challenged many times
over a period of nine years without evidence of irreversible change. It is my feeling,
and I think the feeling of many, that the chronic reversible obstructive, or acute, air-
way pattern that follows reaginic type allergy does not lean to irreversible change.
In other words, it is not a pathogenic mechanism in what is called "emphysema."
DR. PHILIP PATERSON: Your pictures clearly showed an immediate-type re-
sponse. But the point I would like to get across is that if a cell-mediated response was
of first order importance in pigeon disease, one might have no evidence of cutaneous
tuberculin-like responses. For example, one of the ways we make a diagonsis of dis-
seminated tuberculosis is on the basis of a negative tuberculin skin test in a patient
who has previously had a positive one. The amount of antigen used in a skin test
might be important. We know from our own work that people exhibiting negative
tuberculin skin tests in association with disseminated tuberculosis, after treatment,
have reappearance of lymphocyte transformation response in Titro before cutaneous
response in vitro to PPD is evident.
DR. VAN ARSDEL: The theme of my talk was to look critically at the mechanism
of tissue damage and, in the best way possible, attempt to establish directly that cir-
culating antibody is responsible for tissue damage. If this is negative, concurrent
studies on cell-mediated hypersensitivity would become even more important. In a
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few attempts to demonstrate in vitro lymphocyte transformation, we found no circulat-
ing antibody, employing the same conditions that are used concurrently to produce
positive tuberculin responses. Unfortunately. I am not certain that the antigen con-
centrations were anywhere comparable. As you know, the concentration of tuberculin
necessary to induce lymphocyte transformation is far higher than that necessary to
produce a positive skin reaction.
DR. ROY PATTERSON: I would like to make an additional comment on Dr.
Philip Paterson's question. I think Dr. Van Arsdel has demonstrated lymphocytic
transformation using cells of people senstiive to pollen antigens, possibly due to cir-
culating antibody. This transformation in itself might not provide conclusive proof
of the type of immune mechanism reactive.
DR. BRAUDE: It seems to me that the most distinctive feature of severe human
asthma is excess of secretion of mucus. If, as Dr. Harford pointed out, the mast cell
is capable of secreting mucus, I don't see how the pertussis model could be a very
good one for human asthma.
DR. SZENTIVANYI: Nobody intends to compare the pertussis-sensitized mouse
with the human asthmatic. What is important is the abnormal pharmacologic and
immunologic activity pattern of the pertussis-sensitized mouse, used as a model to
study the nature of the so-called "constitutional abnormality" in asthma. Furthermore,
hypersecretion of mucus is only one feature of the pathologic physiology of airway
obstruction during astmatic attack. The significance of bronchospasm and bronchial
edema does not appear to be less than that of the accumulation of abnormal mucus. I
personally have seen an asthmatic die in status asthmaticus; next morning at autopsy
the airways were clear without indication of mucus hypersecretion. Finally, without
knowing anything about the receptor-association of such activity, bronchial mucus
secretion appears to be adrenergically inhibited.
DR. VAN ARSDEL: Although off the subject, it should be noted that there is
good evidence that the so-called "pink puffers," patients with uncomplicated obstruc-
tion due to emphysema, are the ones who do well for a surprisingly long time even
though the obstruction is severe. It is only with the complication of bronchitis in a
patient who also has obstructive emphysema that the clinician usually sees trouble.
DR. KILBURN: I don't know if I qualify as an expert, but I will certainly agree
with Dr. Van Arsdel. This was our experience in a four-year prospective study of
patients with respiratory failure. These patients were often 70 years old, and we
found their emphysema by coincidence. The reason they may not have been symptomatic
was because angina or some other disease caused them to be hospitalized, thereby re-
ducing their activity level and minimizing their dyspnea. However, such patients are
tachypneic. It has been my experience that if one wants to detect people with ab-
normal lungs, look for those with elevated respiratory rates.
DR. CARRINGTON: I trust that Dr. Kilburn has not implied that emphysema is
really a harmless disease. It is true many of the patients with pulmonary emphysema
die of a complicating factor, but most of these cases would not develop such complica-
tions if they did not have emphysema in the first place, perhaps myocardial infarction
excepted.
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